UDG Healthcare acquires Incisive Health and Putnam Associates
Category: #health  By Mateen Dalal  Date: 2019-05-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

UDG Healthcare acquires Incisive Health and Putnam Associates
  • Both acquisitions are good cultural & strategic fit and meet the company’s financial hurdle rates while further expanding its current capabilities.
  • UDG would be financing both transactions from its existing cash & debt facilities.

UDG Healthcare plc, (UDG), a leading Ireland-based healthcare advisory service provider, has reportedly announced that it has acquired American healthcare consultancy, Putnam Associates (Putnam) and British healthcare policy & communications consultancy, Incisive Health (Incisive).

Reports cite, the two transactions would be significantly strengthening UDG’s Ashfield Communications & Advisory business. The two acquisitions would be for a combined consideration of approximately $106 million with Putnam costing $88.6 million and Incisive costing $17.7 million.

According to a report by Pharmafield, the Putnam acquisition would be consolidating Ashfield’s growing advisory pillar by introducing significant expertise in product pricing, commercialization, reimbursement as well as market access strategy. Meanwhile, the Incisive acquisition would be adding specialist capability in the public health advocacy domain, supporting clients in obtaining a secure marketing access for their respective brands alongside broader communication services.

The Putnam deal would see an upfront payment of $60 million in addition to a $20.1 million earn-out for over three years along with a further $8.5 million five year earn-out. The Incisive deal would be seeing an initial consideration of approximately $10.4 million with a $7.3 million earn-out that would be payable over a three-year period.

The CEO of UDG Healthcare, Brendan McAtamney stated that the company is thrilled to announce the acquisition, which would be further enhancing the capabilities of its Ashfield Communications & Advisory. McAtamney further added that both Putnam and Incisive acquisitions are a good cultural & strategic fit for the company and meet its target financial-hurdle rates while also expanding its present capabilities.

According to reports, UDG would be financing both the transactions from its existing cash & debt facilities. The transactions are expected to provide a return on capital that is employed in excess of the company’s 15% target within three years.

Source Credit:

https://www.udghealthcare.com/media/press-releases/udg-healthcare-significantly-strengthens-its-ashfield-communications-and-advisory-business-with-two-acquisitions-for-a-combined-consideration-of-up-to-106-million

https://pharmafield.co.uk/pharma_news/udg-healthcare-acquires-putnam-associates-and-incisive-health/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Peraton to acquire innovative IT solutions provider Solers Inc.
Peraton to acquire innovative IT solutions provider Solers Inc.
By Mateen Dalal

Virginia-based Peraton, a defense and intelligence contractor owned by private equity firm Veritas Capital, reportedly announced that it has signed a definitive agreement to acquire Solers Inc., a leading provider of software development and cybersec...

Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
By Mateen Dalal

A clinical-stage immune-oncology company, Forty Seven, Inc., that works to develop therapies targeting cancer immune evasion pathways, has revealed clinical data from Phase 1b/2. The company is evaluating a new drug combination of Recombinant Human A...

FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
By Mateen Dalal

NuCana is on its way to open a Global Phase III study of Acelarin in combination with cisplatin for patients who are suffering from the disease in 2019 NuCana plc recently announced that it has received Orphan Drug Designation for Acelarin, an inves...